EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Effects of Cimetidine and Dolutegravir on the Endogenous Drug–Drug Interaction Biomarkers for Organic Cation Transporter 2 and Multidrug and Toxin Extrusion Protein 1 in Healthy Volunteers

Tomoki Koishikawa, Kaku Fujiwara, Kunal Taskar iD, Maciej J Zamek-Gliszczynski, Kenta Yoshida iD, Xiaoyan Chu iD, Hideki Hirabayashi iD, Jialin Mao, Kevin Rockich, Tadayuki Takashima, Yoshiyuki Yamaura, Yurong Lai iD und 6 weitere

Clinical Pharmacology & Therapeutics · 2025

DOI: 10.1002/cpt.3482 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Tomoki Koishikawa und 17 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo City, Japan. Hauptthemen laut MEDLINE: Cimetidine, Organic Cation Transporter 2, Organic Cation Transport Proteins, Heterocyclic Compounds, 3-Ring. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study was designed to assess the quantitative performance of endogenous drug–drug interaction (DDI) biomarkers ( N 1‐methylnicotinamide (1‐NMN), N 1‐methyladenosine (m 1 A), and creatinine) for the organic cation transporters, OCT2 and MATE1/2K in the kidney. Ten healthy volunteers received cimetidine (400 and 800 mg, single dose) or dolutegravir (50 mg, twice a day) together with metformin (500 mg). Cimetidine and dolutegravir were considered to act mainly as MATE1/2K and OCT2 inhibitors, respectively. The renal clearance (CL r ) of metformin was decreased by 15.5% and 42.5% by cimetidine 400 and 800 mg, and by 26.8% and 56.9% by dolutegravir first and fifth doses, respectively. CL r ratio (CL r R) of 1‐NMN were 0.93 and 0.64 for cimetidine 400 and 800 mg, and 0.87 and 0.47 for dolutegravir first and fifth doses, respectively. CL r R of m 1 A was less than that of 1‐NMN: 1.0 and 0.80 for cimetidine 400 and 800 mg, and 0.77 and 0.71 for dolutegravir first and fifth doses, respectively. CL r of creatinine was significantly decreased only by cimetidine 800 mg. Individual CL r R of 1‐NMN and m 1 A showed a positive correlation with the corresponding CL r R of metformin with r 2 of 0.58 and 0.55, respectively. When evaluated individually, m 1 A showed a better correlation during cimetidine periods ( r 2 0.64) than 1‐NMN ( r 2 0.36), but vice versa during dolutegravir periods ( r 2 1‐NMN, 0.80; m 1 A, 0.32). These results suggest that 1‐NMN and m 1 A might be more promising than creatinine as endogenous biomarkers for quantitatively assessing the DDI potential of investigational drugs for OCT2 and MATE1/2K based on their CL r R change.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CimetidineOrganic Cation Transporter 2Organic Cation Transport ProteinsHeterocyclic Compounds, 3-RingHumansOxazinesPiperazinesDrug InteractionsPyridonesMaleAdultMetforminBiomarkersHealthy VolunteersCreatinineYoung AdultFemaleNiacinamideAdenosineKidneyDolutegravir

Substanzen

OxazinesPiperazinesCimetidineOrganic Cation Transporter 2Organic Cation Transport ProteinsPyridonesMetforminHeterocyclic Compounds, 3-RingBiomarkersCreatinine

Autor:innen und Institutionen

  • Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo City, Japan.
  • Drug Metabolism and Pharmacokinetic, GSK, Stevenage, UK.
  • Drug Metabolism and Pharmacokinetic, GSK, Collegeville, Pennsylvania, USA.
  • Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA.
  • Department of Pharmacokinetics, Dynamics, Metabolism, and Bioanalytics, Merck & Co., Inc., Rahway, New Jersey, USA.
  • Center of Excellence for Drug Metabolism, Pharmacokinetics and Modeling, Preclinical and Translational Sciences, Research, Takeda Pharmaceutical Company Limited, Kanagawa, Japan.

ORCID-Profile: Kunal Taskar, Kenta Yoshida, Xiaoyan Chu, Hideki Hirabayashi, Yurong Lai, Kazuya Maeda, Yuichi Sugiyama

Zitieren

APA

Koishikawa, T., Fujiwara, K., Taskar, K., Zamek-Gliszczynski, M. J., Yoshida, K., Chu, X., Hirabayashi, H., Mao, J., Rockich, K., Takashima, T., Yamaura, Y., Lai, Y., Tomoda, Y., Kito, T., Maeda, K., Furihata, K., Sugiyama, Y., & Kusuhara, H. (2025). Effects of Cimetidine and Dolutegravir on the Endogenous Drug–Drug Interaction Biomarkers for Organic Cation Transporter 2 and Multidrug and Toxin Extrusion Protein 1 in Healthy Volunteers. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3482

Vancouver

Koishikawa T, Fujiwara K, Taskar K, Zamek-Gliszczynski MJ, Yoshida K, Chu X, et al. Effects of Cimetidine and Dolutegravir on the Endogenous Drug–Drug Interaction Biomarkers for Organic Cation Transporter 2 and Multidrug and Toxin Extrusion Protein 1 in Healthy Volunteers. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3482

BibTeX
@article{Koishikawa2025,
  author = {Koishikawa, Tomoki and Fujiwara, Kaku and Taskar, Kunal and Zamek-Gliszczynski, Maciej J and Yoshida, Kenta and Chu, Xiaoyan and Hirabayashi, Hideki and Mao, Jialin and Rockich, Kevin and Takashima, Tadayuki and Yamaura, Yoshiyuki and Lai, Yurong and Tomoda, Yukana and Kito, Tomoko and Maeda, Kazuya and Furihata, Kenichi and Sugiyama, Yuichi and Kusuhara, Hiroyuki},
  title = {Effects of Cimetidine and Dolutegravir on the Endogenous Drug–Drug Interaction Biomarkers for Organic Cation Transporter 2 and Multidrug and Toxin Extrusion Protein 1 in Healthy Volunteers},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1002/cpt.3482}
}
Kostenlos starten →